Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MM

Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MM

User Photo
VJHemOnc

2 years
178 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Clinical trials and research, regardless of their degree of success, provide useful lessons that can be applied to a range of areas, including future trial design and treatment preconceptions. In this interview, Keith Stewart, MD, ChB, of the Mayo Clinic, Scottsdale, AZ, discusses important lessons learned from the successful overall survival results of the ongoing ASPIRE trial (NCT01080391). Dr Stewart highlights what the results tell us about adding a third drug to combination therapies for relapsed multiple myeloma (MM) patients and at what stage of relapse patients should be treated. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay
>